Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences (SLDB), a precision genetic medicines developer focused on neuromuscular and cardiac diseases, has announced its participation in three major investor conferences in Miami, FL during March 2025.
The company's leadership, including President and CEO Bo Cumbo and Chief Medical Officer Dr. Gabriel Brooks, will present at:
- Leerink Global Healthcare Conference - March 12, 2025, at 9:20 am ET
- Barclays 27th Annual Global Healthcare Conference - March 13, 2025, at 9:30 am ET
- Wedbush Securities' Cardiometabolic Conference - March 10, 2025
Live webcasts will be available on the company's website's Investors section, with replays archived for 30 days. Institutional investors can arrange meetings through Leerink or Barclays representatives.
Solid Biosciences (SLDB), un sviluppatore di medicinali genetici di precisione focalizzato sulle malattie neuromuscolari e cardiache, ha annunciato la sua partecipazione a tre importanti conferenze per investitori a Miami, FL, nel marzo 2025.
La leadership dell'azienda, inclusi il Presidente e CEO Bo Cumbo e il Direttore Medico Dr. Gabriel Brooks, presenterà durante:
- Leerink Global Healthcare Conference - 12 marzo 2025, alle 9:20 ET
- Barclays 27th Annual Global Healthcare Conference - 13 marzo 2025, alle 9:30 ET
- Wedbush Securities' Cardiometabolic Conference - 10 marzo 2025
Le dirette web saranno disponibili nella sezione Investitori del sito web dell'azienda, con le registrazioni archiviate per 30 giorni. Gli investitori istituzionali possono organizzare incontri attraverso i rappresentanti di Leerink o Barclays.
Solid Biosciences (SLDB), un desarrollador de medicamentos genéticos de precisión enfocado en enfermedades neuromusculares y cardíacas, ha anunciado su participación en tres importantes conferencias para inversores en Miami, FL, durante marzo de 2025.
El liderazgo de la empresa, incluyendo al Presidente y CEO Bo Cumbo y al Director Médico Dr. Gabriel Brooks, presentará en:
- Leerink Global Healthcare Conference - 12 de marzo de 2025, a las 9:20 am ET
- Barclays 27th Annual Global Healthcare Conference - 13 de marzo de 2025, a las 9:30 am ET
- Wedbush Securities' Cardiometabolic Conference - 10 de marzo de 2025
Las transmisiones en vivo estarán disponibles en la sección de Inversores del sitio web de la empresa, con repeticiones archivadas durante 30 días. Los inversores institucionales pueden organizar reuniones a través de representantes de Leerink o Barclays.
Solid Biosciences (SLDB)는 신경근육 및 심장 질환에 초점을 맞춘 정밀 유전자 의약품 개발업체로, 2025년 3월 플로리다주 마이애미에서 열리는 세 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사의 리더십, 사장 겸 CEO Bo Cumbo와 최고 의료 책임자 Dr. Gabriel Brooks를 포함하여, 다음과 같이 발표할 예정입니다:
- Leerink Global Healthcare Conference - 2025년 3월 12일, 오전 9:20 ET
- Barclays 제27회 연례 글로벌 헬스케어 컨퍼런스 - 2025년 3월 13일, 오전 9:30 ET
- Wedbush Securities의 심혈관 대사 회의 - 2025년 3월 10일
실시간 웹캐스트는 회사 웹사이트의 투자자 섹션에서 제공되며, 재방송은 30일 동안 보관됩니다. 기관 투자자는 Leerink 또는 Barclays 대표를 통해 회의를 조정할 수 있습니다.
Solid Biosciences (SLDB), un développeur de médicaments génétiques de précision axé sur les maladies neuromusculaires et cardiaques, a annoncé sa participation à trois grandes conférences pour investisseurs à Miami, FL, en mars 2025.
La direction de l'entreprise, y compris le Président et CEO Bo Cumbo et le Directeur Médical Dr. Gabriel Brooks, présentera lors de :
- Leerink Global Healthcare Conference - 12 mars 2025, à 9h20 ET
- Barclays 27th Annual Global Healthcare Conference - 13 mars 2025, à 9h30 ET
- Wedbush Securities' Cardiometabolic Conference - 10 mars 2025
Des webinaires en direct seront disponibles dans la section Investisseurs du site web de l'entreprise, avec des rediffusions archivées pendant 30 jours. Les investisseurs institutionnels peuvent organiser des réunions par l'intermédiaire des représentants de Leerink ou de Barclays.
Solid Biosciences (SLDB), ein Entwickler von präzisen genetischen Medikamenten, der sich auf neuromuskuläre und Herzkrankheiten konzentriert, hat seine Teilnahme an drei wichtigen Investorenkonferenzen in Miami, FL, im März 2025 angekündigt.
Die Unternehmensführung, einschließlich Präsident und CEO Bo Cumbo und Chief Medical Officer Dr. Gabriel Brooks, wird präsentieren bei:
- Leerink Global Healthcare Conference - 12. März 2025, um 9:20 Uhr ET
- Barclays 27th Annual Global Healthcare Conference - 13. März 2025, um 9:30 Uhr ET
- Wedbush Securities' Cardiometabolic Conference - 10. März 2025
Live-Webcasts werden im Bereich Investoren der Unternehmenswebsite verfügbar sein, mit Aufzeichnungen, die 30 Tage lang archiviert werden. Institutionelle Investoren können Meetings über Vertreter von Leerink oder Barclays arrangieren.
- None.
- None.
CHARLESTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- Leerink Global Healthcare Conference – Miami, FL
Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat on Wednesday, March 12, 2025, at 9:20 am ET.
- Barclays 27th Annual Global Healthcare Conference – Miami, FL
Mr. Cumbo and Dr. Brooks will participate in a fireside chat on Thursday, March 13, 2025, at 9:30 am ET.
Solid is also a participating company at Wedbush Securities’ Cardiometabolic Conference taking place on Monday, March 10, 2025, in Miami, FL.
Live webcasts of the presentations will be available on the Events page of the Investors section of the Company website or by clicking here. Webcast replays will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their Leerink or Barclays representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When is Solid Biosciences (SLDB) presenting at the Leerink Global Healthcare Conference 2025?
How can investors access SLDB's March 2025 conference presentations?
Which executives from SLDB are presenting at the March 2025 healthcare conferences?
What investor conferences is Solid Biosciences (SLDB) attending in March 2025?
How can institutional investors arrange meetings with SLDB management during the conferences?
